20xx中國(guó)國(guó)際醫(yī)藥高峰論壇上的演講(ppt30中英文)-演講技能-資料下載頁(yè)
2025-08-08 11:40本頁(yè)面
【導(dǎo)讀】KeyFactorsforR&D影響研發(fā)的關(guān)鍵因素。DriveR&DtoMarket將研發(fā)推向市場(chǎng)。超過(guò)90%將會(huì)以失敗告終。在2020年，美國(guó)市場(chǎng)占全球市場(chǎng)的%，然而歐洲市場(chǎng)僅僅占%。
【正文】 建立綜合的研究計(jì)劃（短 /中 /長(zhǎng)期） ? Inlicense/cooperate with local and international partners 與當(dāng)?shù)睾蛧?guó)際伙伴合作 ? Build up strong clinical development and marketing skills 掌握有效的臨床開發(fā)和營(yíng)銷技巧 What local panies will do 當(dāng)?shù)毓疽鍪裁矗? International Industry 國(guó)際醫(yī)藥行業(yè) ? China being outsourcing center for drug development and manufacturing 中國(guó)正在成為藥物開發(fā)和生產(chǎn)的外包中心 ? Preclinical costs in China are, on average, 20% of the US 中國(guó)的臨床前成本平均為美國(guó)的 20% ? Big pharmas are rapidly increasing outsourcing to China 大型醫(yī)藥公司在中國(guó)的外包業(yè)務(wù)快速增長(zhǎng) ? China’s domestic market being significant 中國(guó)國(guó)內(nèi)市場(chǎng)日趨重要 ? Healthcare system privatized。 insurance industry growing 醫(yī)療體系私有化， 保險(xiǎn)業(yè)快速增長(zhǎng) ? Large patient base 眾多的病患 ? China is developing its own expertise 中國(guó)正在發(fā)展自身的專業(yè)技術(shù) ? Chemistry services 化學(xué)領(lǐng)域的服務(wù) ? Modification of traditional Chinese medicine(TCM) 優(yōu)化中藥 ? Many startups 新興領(lǐng)域 ? Outsourcing 外包 ? Technology transfer/Strategic alliances技術(shù)轉(zhuǎn)讓 /戰(zhàn)略聯(lián)盟 ? Captive Ramp。D investment研發(fā)投資 ? Advanced technology: significant investment (NIH $28 billion in 2020) 先進(jìn)技術(shù)：重要的投資 ? Needs lowcost drug development solutions 需要進(jìn)行低成本藥物開發(fā) ? Largest markets 廣闊的市場(chǎng) ? FDA pliant 適應(yīng) FDA ? Strong petition 激烈的競(jìng)爭(zhēng) Developed Pharma Market發(fā)達(dá)醫(yī)藥市場(chǎng) ? Needs advanced technology: “l(fā)ate starter” 后來(lái)者：需要先進(jìn)的技 術(shù) ? Low drug development cost 低廉藥物開發(fā)成本 ? Current market small 市 場(chǎng)目前狹小 ? Generally not yet FDA pliant 基本不適應(yīng) FDA ? High market growth 市 場(chǎng)增長(zhǎng)快 China中國(guó) Opportunities: Integrate China into global market 將中國(guó)融入全球市場(chǎng) ? More clinical development in China 在中國(guó)進(jìn)行更多的臨床領(lǐng)域開發(fā) ? Ramp。D in China own Ramp。D centers, cooperation and outsourcing 在中國(guó)擁有研發(fā)中心，公司和外包業(yè)務(wù) ? Adapt their research portfolio to China’s need 根據(jù)中國(guó)需要對(duì)研究領(lǐng)域分配進(jìn)行調(diào)整 ? Integrate China into their global Ramp。D program 將中國(guó)融入全球研發(fā)計(jì)劃 What international panies will do 國(guó)外公司要做什么？ Summary 總結(jié) ? Global industry needs to lower Ramp。D cost and increase productivity 全球醫(yī)藥行業(yè)需要降低研發(fā)成本提高生產(chǎn)力 ? Chinese industry needs new products and clinical development and marketing expertise 中國(guó)醫(yī)藥行業(yè)需要新產(chǎn)品和臨床開發(fā)與營(yíng)銷的專業(yè)技術(shù) ? Strong life science Ramp。D cluster are emerging in China 強(qiáng)大的生命科學(xué)研發(fā)集群在中國(guó)形成 ? China has excellent scientists and offers low cost 中國(guó)擁有出色的科研人員；成本支出 較低 ? Attractive market and consistent policies are the most powerful tool to achieve success 有吸引力的市場(chǎng)和與市場(chǎng)相一致的政策是取得成功的關(guān)鍵 ? Move standards step by step to international level 逐步提高到國(guó)際化水平 ? Develop prehensive incentive system, (tax, price, listing, etc.) in order to encourage Ramp。D investment 形成綜合激勵(lì)體系來(lái)鼓勵(lì)研發(fā)投資
試題試卷相關(guān)推薦
鄂ICP備17016276號(hào)-1